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Prediction of Mortality After ALPPS Stage-1
An Analysis of 320 Patients From the International ALPPS Registry
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Objectives: The aim of this study was to identify predictors of 90-day
mortality after Associating Liver Partition and Portal Vein Ligation for Staged
Hepatectomy (ALPPS), available after stage-1, either to omit or delay stage-2.
Background data: ALPPS is a two-stage hepatectomy for patients with
extensive liver tumors with predicted small liver remnants, which has been
criticized for its high mortality rate. Risk factors for mortality are unknown.
Methods: Patients in the International Registry undergoing ALPPS from
April 2011 to July 2014 were analyzed. Primary outcome was 90-day
mortality. Liver function after stage-1 was assessed using the criteria of
the International Study Group for Liver Surgery (ISGLS) after stage-1 among
others. A multivariable model was used to identify independent predictors of
90-day mortality.
Results: Three hundred twenty patients registered by 55 centers worldwide
were evaluated. Overall 90-day mortality was 8.8% (28/320). The predom-
inant cause for 90-day mortality was postoperative liver failure in 75% of
patients. Fourteen percent of patients developed liver failure according to
ISGLS criteria already after stage-1 ALPPS. Those and patients with a model
of end-stage liver disease (MELD) score more than 10 before stage-2 were at
significantly higher risk for 90-day mortality after stage-2 with an odds ratio
(OR) 3.9 [confidence interval (CI) 1.4–10.9, P¼ 0.01] and OR 4.9 (CI 1.9–
12.7, P¼ 0.006), respectively. Other factors, such as size of future liver
remnant (FLR) before stage-2 and time between stages, were not predictive.
Conclusions: This analysis of the largest cohort of ALPPS patients so far
identifies those patients in whom stage-2 ALPPS surgery should be delayed or
even denied. These findings may help to make ALPPS safer.
Keywords: hepatectomy, liver neoplasms, liver regeneration, portal vein
(qualifier surgery)
(Ann Surg 2015;262:780–786)
A ssociating Liver Partition and Portal Vein Ligation for StagedHepatectomy (ALPPS) is a novel two-stage hepatectomy that
induces rapid growth of the liver remnant in primarily nonresectable
liver tumors by combining transection of the liver with portal vein
ligation.1,2 The procedure was initially developed to avoid liver
failure by rapid volume enhancement of the future liver remnant
(FLR), but high mortality rates have been reported. This has led to an
ongoing debate about the safety of ALPPS.
The international ALPPS registry monitors feasibility and
safety of ALPPS. The first analysis of 202 patients in January
2014 reported a 90-day mortality of 9% and a liver failure rate of
9%. The majority of registered deaths were due to liver failure, but an
analysis of the risk factors for mortality was unsuccessful due to the
low event rate.3
Themajorityof deaths and thedevelopment of posthepatectomy
liver failure (PHLF) occur after the completion hepatectomy in stage-
2. The goal of the current study is to identify risk factors, which may
help clinicians to avoid adverse outcomes before performing stage-2.
Although the high feasibility rate is considered to be themajor strength
of ALPPS by many, the two stages also allow a delay or even
cancellation of stage-2, if the risk is too high or may be modified.
MATERIAL AND METHODS
Study Design and Study Setting
This observational study is based on data from the international
ALPPS registry. It is administered by the Clinical Trials Center at the
University of Zurich and approved by the Ethics Committee of the
Canton of Zurich, Switzerland, and is registered at Clinicaltrials.gov
(NCT01924741). Centers enter patient data using the web-based
SECUTRIAL clinical trials software. Data entry is monitored through
a query and answer system maintained by a dedicated study nurse. A
request submitted to study postoperativemortality and liver failurewas
made by the authors and approved by the Scientific Committee of the
ALPPS registry on August 14, 2014. Data export and analysis was
performed in October 2014.
Participants
Patients were consented to have their data entered into the
International Registry according to requirements of local ethics
committees. All patients entered by centers between the inception
of the registry on October 1, 2012 and September 30, 2014 were
eligible in this analysis. Patient data were screened for complete
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outcome data, that is, patient follow-up at least 90 days after stage-2
with information about death or survival of the patients as well as
information about postoperative liver function.
Variables
Data on patient demographics, tumor type and prior therapy,
comorbidities, histology, volumetry, and procedure details were
extracted. Volumetric data were entered on the basis of imaging
performed in each center. Standardized total liver volume (sTLV)
was calculated according to the Vauthey formula.4
Main outcome measure of this study was 90-day mortality in a
multivariable analysis of clinically modifiable risk factors. Any death
occurring during the postoperative 90-day period in the presence of at
least one of the liver failure criteria was considered a liver-related
mortality.
Secondary outcomes included four different definitions of
PHLF:
(1) 50–50 criteria are considered positive when the prothrombin
time index is less than 50% ( International normalized ratio
(INR) 1.7) and serum bilirubin is more than 50micromol/L
(2.9mg/dL) on postoperative day 5, predicting a mortality of
50%.5
(2) DAY5bil>7 criterion is considered positive when bilirubin is
more than 7mg/dL in noncirrhotic, noncholestatic patients on
day 5 after surgery. The DAY5bil>7 criterion is different but
close to the PEAKbil>7 criterion published by Mullen et al.
6 The
Mullen criterion had to be modified because in the ALPPS
registry, only bilirubin levels at postoperative day 5 are recorded
and a peak value cannot be assessed.
(3) International Study Group for Liver Surgery (ISGLS) criteria are
positive when INR and bilirubin were above the normal cut-off
as defined by the local laboratory on day 5 after liver resection.7
Because the registry data relate to many different local labora-
tory standards, we set an INR of 1.3 and bilirubin of more than
20micromol/L (1.2mg/dL). Biliary complications did not
exclude patients from being positive for liver failure, as in
the published definition.7
(4) Clinicians’ assessment criterion is positive, when clinicians
entering the data into the registry checked of the box ‘‘yes’’
after the question if patients, according to their clinical judg-
ment, developed PHLF.
Postoperative complications were recorded by clinicians in the
registry as the highest complication grade occurring after each stage
using the Clavien-Dindo classification.8,9
All patients, who died within 90 days after ALPPS, were listed
and analyzed in detail according to the following five categories: (1)
demographic factors age and tumor type;3 (2) liver function, assessed
by histology and the presence of cholestasis; (3) surgical severity
factors, assessed by blood transfusion and duration of surgery;3 (4)
liver function after stage-1 by ISGLS criteria and MELD score; and
(5) sFLR prior to stage-2. Outcomes are assessed by the presence of
any of the four above-listed liver failure criteria, the most severe
complication, the direct cause leading to death, and the root cause
according to the judgment of the authors according to a methodology
widely used to investigate adverse events in health care.10
Bias and Study Size
Patients with incomplete outcomes data were excluded, intro-
ducing a reporting and incomplete reporting bias whereby patients
with negative outcome are either not getting reported at all or are in
the excluded group of patients.11 An on-site auditing to avoid such
biases is currently not available in the registry.
Quantitative Variables and Statistical Methods
Data were expressed using means and standard deviation (SD)
for normally distributed, and median and interquartile ranges (IQRs)
for skewed data. In univariate analyses, P values less than 0.05 were
considered significant. Multivariable binary logistic regression
analyses were performed with the endpoint 90-day mortality using
backward elimination removing variable until all have individual P
values are less than 0.10. All covariates with significant correlations
in univariate analysis or those with clinical importancewere included
in the analysis. Covariates representing competing risks were
selected by choosing the covariate that is clinically most important
and modifiable. Receiver-operating characteristic curves (area under
the curve, AUC) and the area under the AUC curve (c-statistic) were
used to find discrimination thresholds. All statistical analyses were
performed using SPSS version 22 forMac (IBMCorp, Armonk, NY).
RESULTS
Participants
During the study period, 73 centers entered patient data on 406
patients undergoing ALPPS. Eighty-six patients (21%) had to be
excluded due to missing information on 90-day mortality, either
because 90 days after surgery were not reached or because centers,
despite repeated requests, failed to complete this information (Supple-
mentary Figure 1, http://links.lww.com/SLA/A878). In 320 patients,
90-day survival and liver function data were available and confirmed.
Descriptive Data
The characteristics of the study population are provided in
Table 1. The mean age was 60 years, and 72% of patients suffered
from colorectal liver metastases. The majority of patients with
colorectal liver metastases underwent chemotherapy.
Causes of the Mortality After ALPPS
Supplementary Table 1, http://links.lww.com/SLA/A877 lists
all 28 patients who died within 90 days after ALPPS. The table
displays the known risk factors for poor outcomes defined so far. In
only five patients, the sFLR before stage-2 was less than 0.3. PHLF
was the most common complication in patients and septic shock the
most common direct cause of death. Errors in patient selection and
liver function assessment were the two most common root causes for
patient mortality.
Association of Liver Failure and Mortality
Three hundred fifteen out of 320 patients (98.4 %), who
underwent ALPPS stage-1, reached stage-2 resection, while five
patients did not (Supplementary Table 2, http://links.lww.com/SLA/
A877). The 90-daymortality of the 315 patients, who underwent both
stages, was 8.8%. The 90-day mortality for all patients with CLRM
was 5%. The table illustrates the incidence of liver failure after
ALPPS stage-2. Nine percent experienced liver failure after stage-2
by 50–50 criteria, 7% by DAY5Bili> 7criteria, and 30% by ISGLS
criteria after stage-2. DAY5Bili> 7 criteria had the highest accuracy
with a positive predictive value of 33% and a negative predictive
value of 94% for 90-day mortality. Liver failure by the same three
criteria was a rare event after ALPPS stage-1 in 1%, 2%, and 14% of
patients positive for 50–50% criteria, DAY5Bili>7 criteria, and
ISGLS criteria, respectively.
For patients, who fulfilled 50-50, DAY5Bil>7 and ISGLS
criteria, 90-day mortality was 23%, 28% and 18%, respectively.
Twenty-one of the twenty-eight 90-day mortalities after ALPPS
(75%) were positive for one of the liver failure criteria and were
considered to be liver-related 90-day mortalities.
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Preoperative Laboratory Tests Prior to Stage-2 and
Mortality
Figure 1 shows the predictive value of laboratory tests for 90-
day mortality before stage-2 ALPPS. Figure 1 A and C show that
bilirubin and creatinine levels before stage-2 were strong predictors
of mortality after stage-2. INR before stage-2 showed no significant
association (Fig. 1B). Increase of bilirubin between stage-1 and 2 was
also a significant predictor (Fig. 1D). Using the MELD score to
combine all three laboratory values yielded the highest AUC of 0.73
[confidence interval (CI) 0.60–0.86]. The best cut-off giving weight
to sensitivity and specificity was a MELD score of at least 10
(Fig. 1E) resulting in an AUC of 0.79 (CI 0.67–0.92) for liver-
related mortality (Fig. 1F).
Multivariate Analysis of Mortality ISGLS Criteria
After Stage-1 and Meld Score Before Stage-2
Liver failure after stage-1 andMELD scorewere entered into a
multivariate model encompassing factors known or suspected to
affect outcomes after ALPPS to adjust for confounders (Fig. 2).
Age, primary liver tumors, operative time more than 5 hours during
stage-1, and the administration of red blood cell (RBC) transfusions
during either stage were significant predictive risk factors for 90-day
mortality. In addition, patients who met ISGLS criteria for PHLF
after stage-1 had an adjusted odds of 3.9 (CI 1.4–10.9) and patients
with a MELD score at least 10 MELD before stage-2 had an adjusted
odds of 90-day mortality of 4.9 (CI 1.9–12.7). Charlson score, sFLR
before stage-2, sex, center volume, and time between stages had no
significant impact on outcome in the model.
ALPPS Outcomes Stratified by Risk Groups
Figure 3 A to F shows the incidence of the three outcomes: (1)
complications of Clavien-Dindo grade at least IIIA, (2) liver failure
according to ISGLS criteria, and (3) 90-day mortality for the sub-
groups of patients stratified by risk factors analyzed in this study:
Age, tumor types, ISGLS criteria after stage-1, and MELD score
before stage-2 stratify to different outcomes in this univariate
analysis, while sFLR volume before stage-2 and center experience
do not. Mortality was 14% for patients older than 60 years, 71% and
36% for patients with gallbladder cancer and cholangiocarcinoma,
respectively, 20% for patients who fulfilled ISGLS criteria after
stage 1, and 22% for patients with a MELD score more than
10 before stage 2.
DISCUSSION
This analysis of the International ALPPS registry demon-
strates that occurrence of liver failure according to the ISGLS criteria
after stage 1 and a MELD score at least 10 before stage-2 are
independent predictors of 90-day mortality, in addition to previously
defined risk factors. Both predictors identify a high-risk population
and may be used to guide the surgeon when or even whether stage-2
should be performed. The findings of this study imply that the stage-2
operation might be deferred as long as the MELD score is at least 10.
The main goal of this study was to provide a useful and easy
applicable tool to identify those patients after stage-1 operation who
are at a higher risk for death after stage-2 operation. Global liver
function between stages is crucial for success and failure of this novel
and complex procedure. ISGLS criteria and MELD score reflect the
excretory and synthetic liver function and we observed that liver
function is significantly compromised by portal vein ligation and
parenchymal transection. Directing the entire blood flow through the
small liver remnant at stage-1 causes liver failure by ISGLS criteria
in 14% of patients after ALPPS stage-1. This study suggests that
TABLE 1. Main Characteristics of 320 Patients in the ALPPS
Registry 2012–2014
Variable of Interest
All Patients
(n¼ 320)
Age, mean (SD) 60 (12.4)
Median (IQR) 61 (IQR 53–68)
Sex, female/male, number 124/196
(%) (39%/61%)
Ethnic origin, white, number (%) 299 (93%)
Asian, number (%) 13 (4%)
Other, number (%) 8 (3%)
Tumor type, CRLM, number (%) 228 (72%)
Non-CRLM 26 (8%)
HCC, number (%) 32 (10%)
IHCC, number (%) 13 (4%)
PHCC, number (%) 14 (4%)
GBCA, number (%) 7(2%)
Charlson index (1–14), mean (SD) 7.2 (1.9)
Median (IQR) 7 (IQR 6–9)
Histological abnormalities,y data
available (100%)
188 (100%)
Macro-steatosis, number (%) 60 (32%)
Macro-steatosis, number (%) 16 (9%)
Fibrosis 51 (27%)
SOS 37 (20%)
Chemotherapy before ALPPS, data available 308 (100%)
Overall patients with chemotherapy 209 (67%)
CLRM patients, data available 203 (100%)
Patients with CLRM who had chemotherapy,
number (%)
203/217 (94%)
Patients with other tumors than CRLM with
chemotherapy
6 (2%)
sFLR before stage-1, mean (SD)z 0.21 (0.15)
Median (IQR) 0.21 (0.12–0.27)
Number of patients with starting
sFLR <0.15 (%)
49 (15%)
sFLR before stage-2, mean (SD) 0.4 (0.13)
Median (IQR) 0.4 (0.31–0.46)
Time between stages, days, mean (SD) 14.1 (11.2)
Median (range) 10 (5–70)
Procedure duration stage-1, minutes,
mean (SD)
325 117
Median (IQR) 310 (259–390)
RBC transfusion during either stage,
data available
312 (100%)
Yes 106 (34%)
No 206 (66%)
Kinetic growth in sFLR/week, mean (SD) 0.16 (0.14)
Median (IQR) 0.13 (0.07–0.20)
Year in which ALPPS was performed
2011, number (%) 35 (10%)
2012, number (%) 133 (42%)
2013, number (%) 115 (36%)
2014, number (%) 37 (12%)
Experience of center performing ALPPS
Low volume (<10 procedures) number of
patients/centers
157 (49%)
in 9 centers
High volume (10 procedures) number of
patients/number of centers
163 (51%)
in 46 centers
‘‘Data available’’ refer to the number of patients in the registry with complete
information about the respective variable.
Charlson index is a validated method to quantify comorbidities.
ySeveral histologic abnormalities may be present in one patient.
zKinetic growth was assessed in sFLR per week, as customary.21
CRLM indicates colorectal liver metastases; GBCA, gallbladder carcinoma;
HCC, hepatocellular carcinoma; IHCC, intrahepatic cholangiocarcinoma; NCLRM,
noncolorectal liver metastases; PHCC, perihilar cholangiocarcinoma; sFLR,
standardized future liver remnant according to Vauthey et al.
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stage-1 ALPPS might be considered as a liver function ‘stress test’
and patients who develop liver failure after stage-1 are not good
candidates to proceed with stage-2 within the 1 week typical for
classical ALPPS. By taking these factors into account, a considerable
proportion of the mortality after ALPPS stage-2 may be preventable.
Although more sophisticated liver function tests such as
intraoperative ICG,12 mebrofenin scintigraphy (HIDA),13 and
LiMAX14 test may be more specific in assessing liver function than
routine laboratory parameters, such tests require special devices and
are not routinely available in many centers.15 The advantage of the
ISGLS criteria andMELD score is that both are readily available and
easily accessible in all hepatobiliary centers worldwide. Although
the MELD score is normally used to estimate the survival
probability of patients with end-stage liver disease on the liver
transplant waiting list, the criterion of MELD score at least
10 immediately before stage-2 had a good discriminatory power
with a c-statistic of 0.79.
Another important finding of the study is that any bilirubin
more than 2mg/dL or 37micromol/L before stage-1 or stage-2 as
well as any increase in bilirubin levels between the baseline
level before stage-1 and the baseline level before stage-2 are also
relevant predictors of mortality. In the present multivariate model,
we did not include bilirubin more than 2mg/dL or 37micromol/L
before stage-1, as the few patients with elevated bilirubin
before stage-1 had perihilar cholangiocarcinoma (PHCC) or IHCC
and including both bilirubin more than 2mg/dL and more than
37micromol/L before stage-1 and tumor type would have resulted
in two competing variables in the model. Our previous recommen-
dations regarding primary tumors,3,16 which are also observed by
this study, appropriately address the negative impact of cholestasis
before stage-1 associated with a 33% mortality risk. Therefore,
surgeons should be cautious in the presence of hyperbilirubinemia
also before stage-1, when classical ALPPS is considered as a
resection strategy.
The present analysis demonstrates that the early enthusiasm
for ALPPS-induced rapid hypertrophy led to overemphasis of liver
volume in predicting future liver function. Assessing liver function
between stages using routine laboratory tests now appears more
critical to decide at what time patient should undergo stage-2 ALPPS.
The current analysis demonstrates that the vast majority of patients
(86%) tolerate rapid hypertrophy without developing liver dysfunc-
tion after stage-1. The remaining 14% of patients may simply require
longer recovery after stage-1 and may not tolerate stage-2 ALPPS.
The reportedly high complication and mortality rates may well be
related to the undue use of stage-2 in most patients irrespective of
compromised liver function 1 week after stage-1. This study ana-
lyzed a larger cohort of patients than prior studies on two-stage
hepatectomies and helps to refine criteria to select those ALPPS
patients who are not candidates for classic ALPPS.
The analysis also demonstrates that previously described3 risk
factors for complications, namely, (1) age, (2) tumor type, (3)
duration of stage-1 surgery, and (4) intraoperative blood transfusions,
are also risk factors for mortality. The impact of age and tumors type
as indications of ALPPS on outcomes has been stressed in the first
registry analysis of risk factors for complications at least IIIB and is
again striking in the current analysis of outcomes. ALPPS should be
used with utmost caution in patients older than 60 years and for
indications other than metastatic liver tumors. However, among the
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FIGURE 1. Receiver-operating characteristic curves (ROC) for routine laboratory tests predicting 90-day mortality after ALPPS. A,
Serumbilirubin levels at baseline before stage-2; P, level of significance, AUC, area under the curve; cut-off value giving equal weight
to sensitivity and specificity. B, I levels before stage-2, with no statistically significant correlation. C, Serum creatinine before stage-2.
D, Difference between serum bilirubin before stage-1 and serum bilirubin before stage-2. E, MELD (model of end-stage liver disease
encompassing bilirubin INR and creatinine) before stage-2 as a predictor of 90-day mortality. F, MELD before stage-2 as a predictor
of liver-related 90-day mortality, using death due to liver failure as an endpoint.
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FIGURE 2. Multivariable model of risk factors for 90-day mortality. Adjusted odd ratios and P values are shown in a multivariable
model with the endpoint 90-day mortality. Backward elimination was used until all factors have individual P values <0.10. MELD,
model of end-stage liver disease; ISGLS LF POD 5 poststage-1, liver failure by criteria of the International Study group for Liver
Surgery 5 days after stage-1; procedure duration >5h stage-1, duration of the ALPPS procedure in stage-1 of more than 5hours;
tumor type, primary liver tumor (intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, hepatocellular carcinoma,
gallbladder tumor) versus metastatic liver tumors (colorectal liver metastases, noncolorectal liver metastases); any RBC transfusion
in S1/2: any need for red blood cell transfusion in either stage; Charlson score> 8: Charlson comorbidity index greater than 8; sFLR
before stage-2 size of the standardized future liver remnant as calculated by the Vauthey formula; Center volume > 10 patients,
centers with more than 10 patients performed and completely entered were considered to be high volume centers; time between
stages >10 days, time period between the 2 stages of ALPPS of more than 10 days
FIGURE 3. Predictors of outcome in ALPPS. A, Age60 years is a predictor of 90-day mortality after ALPPS. B, The 90-day mortality
in patients with colorectal liver metastases (CRLM) was 4%, with noncolorectal liver metastases (NCLRM) 0%, and the 90-day
mortality in patients with primary liver tumors is markedly higher. C, International study group for liver surgery (ISGLS) criteria for
liver failure after stage-1 are predictors of liver failure after stage-2 and 90-day mortality. D, Model of end-stage liver disease (MELD)
10 is a predictor of 90-daymortality after ALPPS. E, The size of the liver remnant before stage-2 (standardized future liver remnant-
sFRL according to Vauthey et al4) has no impact on complications and 90-daymortality, but the incidence of liver failure after stage-2
decreases with progressively larger sFLR. F, Complications and mortality are equivalent between low and high volume centers, but
liver failure is less common in high volume centers.
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group of primary liver tumors, hepatocellular carcinoma (HCC) and
intrahepatic cholangiocarcinoma (IHCC) had a more favorable
complication profile and lower rates of liver failure and mortality
than PHCC and gallbladder carcinoma (GBCA). Therefore, if
ALPPS is to be conservatively used in primary liver tumors, IHCC
or HCC may be among better indication and further explorations in
this direction may be justified. Although this analysis attempts to
give a guideline on how to prevent mortality after stage 2 by
assessment of liver function and delay of stage 2, indications for
ALPPS stage 1 should remain fairly restrictive, as stage 1 ALPPS
may, once performed, significantly compromise quality of life and
access to chemotherapy.
Duration of stage 1 (3) and intraoperative blood transfusions
(4) are likely markers of severity and complexity of the surgical
procedure. The search for technical modifications of the procedure
with less invasive surgery as documented by the innovations hybrid-
ALPPS,17 ALTPS,18 RALPP,19 or partial-ALPPS20 reflects the
clinicians’ awareness that classical ALPPS might be too much
surgery for some patients.
The large cohort of patients from 73 centers in 49 different
countries hopefully presents a large sample of all ALPPS patients
operated worldwide. The collaborative effort for data collection
allowed performing a robust analysis on small differences in poten-
tial outcome predictors. However, a registry based on voluntary
reporting has limitations due to a potential reporting bias,11 resulting
in underreporting of unfavorable outcome and mortality. Despite
efforts from our side, data entry could not be completed to include
outcome data in 65 patients, which represent 20% of the entire study
population. Despite this limitation, the risk factor analysis per se,
which is based on large sample, can provide enough useful infor-
mation to clinicians to help to reduce mortality in the future. Another
limitation of this study is related to the design of the registry with
reporting serum bilirubin values at day 5 after each stage. Therefore,
the exact use of the originally described PEAKbil>7 criteria was not
possible. We modified the PEAKbil>7 criterion to theDAY5bil >7mg/
dl criterion. Despite this, the DAY5bil>7 has the highest accuracy to
predict mortality after ALPPS:
In conclusion, ISGLS-defined liver failure at day 5 after stage-
1 and MELD score at least 10 immediately before stage-2 are
independent predictors of poor outcome after ALPPS stage-2. Both
criteria identify high-risk patients for mortality and enable the
surgeon to decide when to proceed to or when to defer the stage-
2 operation. This recommendation may be easily applicable and
hopefully make ALPPS safer.
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DISCUSSANTS
D. Cherqui (Paris, France):
The main results are that either post-stage 1 liver failure
according to ISGLS or pre-stage 2 MELD higher than 10 points
predicted mortality. The authors suggest delaying or canceling stage
2 in the presence of one of these interstage criteria. This is useful
information. I have a few comments and questions. First, 86 cases
(21%) had to be excluded due to missing data. It is not clear how
many were really missing data and how many had just not reached
90-day follow-up. This is inherent to registry data as acknowledged
by the authors. In any case, mortality rates reported here should be
considered the minimal estimate of mortality, as at least some of the
missing cases include fatalities. Second, in this study, sFLR before
stage 2 was not a predictor of 90-day mortality. As the main cause of
mortality is liver failure, this finding suggests dissociation between
volume and function. A highly publicized feature of ALPPS is
rapid interstage hypertrophy. As ALPPS as well as portal vein
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embolization (PVE) are mainly indicated on the basis of insufficient
estimated FLR before major resection, this observation requires
additional comments. Third, ISGLS grade is sensitive to minor
variations and has a low specificity. This suggests that minor changes
in liver functionafter stage 1mayhave amajor impact. It is striking that
bilirubin more than 2mg/dL has a higher impact than liver volume
(IU for bilirubin ismmol/L not mmol). Fourth, despite the fact that the
present study focusedon interstage liver function, previously described
risk factors were confirmed, that is, age, tumor type, durations of stage
1 surgery, and transfusions. Two are related to patient selection, which
was found to be the root cause in 14 of 28 deaths. I read in the
supplement Table 1, http://links.lww.com/SLA/A877.
Age more than 60 years was associated with a 14-fold
increased mortality. This is a limitation of ALPPS, as a large
proportion of patients requiring liver resection for cancer are more
than 60. Next, 90-daymortality after ALPPS for biliary cancer was
47% (gallbladder cancer 71%, perihilar cholangcarcinoma 36%).
These are unacceptable figures. These latter pathologies have
inherent limitations: preoperative hyper-bilirubinemia, bile bacterial
contamination with stents, and need for hilar dissection (RPV
ligation) in the exact area wherein the tumor is located. Is it time
to call biliary cancer a contraindication to ALPPS?
Response From E. Schadde (Zurich, Switzerland):
Thank you for those questions, Prof. Cherqui. First, indeed,
there was a 20% dropout in the last analysis. We tried hard to get
these data and I agree with you that this is a minimum figure. We had
the opportunity to look at a national database on ALPPS recently and
mortality figures were double as high as we are reporting in the
International Registry. It would be reasonable to assume that this is
the case in the worldwide experience as well, but these are the
limitations that we acknowledged in the paper.
Second, minor changes in laboratory values after stage-1
ALPPS predict adverse outcomes. This was an interesting finding
that we were not prepared for when we designed the analysis. We do
think that there is a decrease in liver function after stage-1 ALPPS
that is different than what we would expect in the setting of an
auxiliary arterialized part of the liver. Recent data on LiMAx testing
of patients undergoing ALPPS from the group in Berlin, Germany, as
well as the recent data from the group in Lille, France, show this as
well. There is a decline in liver function after stage 1 that we should
take seriously, and this is the main message of our study. Third, the
question about volume versus function is important. Obviously, it
will be necessary to evaluate not just volume but function and, if
possible, using regional liver function tests. It is unclear whether this
is going to be HIDA scanning or whether there is going to be a
magnetic resonance imaging (MRI) methodology. This is not only
true for ALPPS but also for any procedure wherein you do extended
liver resections. The last issue: We agree that the mortality of ALPPS
for primary liver tumors is prohibitive. We recommend avoiding the
classical ALPPS in these patients, but perhaps we can use a modi-
fication on ALPPS associated with a decreased risk of poor outcome.
J. Figueras (Girona, Spain):
Congratulations for this excellent presentation and thank you
for helping us to better understand themechanismof liver failure in the
ALPPS procedure. In fact, we did a retrospective analysis of our cases,
andwearrived to the same conclusions. First, the indications. This is an
operation mostly for liver metastases. Second one, the age; the liver
hypertrophy in old patients is poorer. The third one, hyper-bilirubi-
nemia after the first procedure. You mention that if bilirubin is higher
than the normal levels, we should wait before doing the second
procedure.We found two additional risk factors. One is the association
of surgery of the primary tumorwith the first procedure and the reverse
approach. What do you think about these two risk factors?
Response From E. Schadde (Zurich, Switzerland):
Thank you Prof. Figueras. In our multivariate model, we did
not look at those two risk factors, that is, complex ALPPS with an
associated procedure during the first stage and the reverse approach.
This ought to be done by other groups. Actually, in the ALPPS
registry, there are several groups, who have approval from the
scientific committee for a variety of analyses. We did not want to
pack everything into the current analysis.
F. Pruvot (Lille, France):
Thank you Dr. Schadde for this presentation. According to the
preliminary report of the French series about 70 patients, we have
shown, as you suggested, that interstage failure was a determinant
factor for poststage 2 morbidity and mortality, but in our work using
scintigraphy we demonstrated a paradox. The reason of the insuffi-
ciency during the interstage is not the failure of the future remnant
liver, but rather the failure of the whole liver, and specifically of the
ligated livers, wherein liver function is depressed. Do you think in
your registry you have the clinical basis of these hypotheses?
Response From E. Schadde (Zurich, Switzerland):
Yes, indeed, I think that our findings go exactly in parallel with
what you show in your most recent study on HIDA scanning.
C. Bruns (Magdeburg, Germany):
Thank you very much for the great presentation. My question
is, because you did not mention it, what about the impact of
chemotherapy on the two different steps of ALPPS? Did you collect
the data if liver function is compromised after the first step of ALPPS
when chemotherapy is administered and does it impact mortality?
Furthermore, I believe it is much more important to develop a score
predicting the outcome with respect to mortality and morbidity
before step 1 of the ALPPS procedure to pre-estimate the liver
function of the FLR instead of developing a score to predict which
patient after step 1 will or will not be able to proceed to step 2 of the
ALPPS procedure.
What is your recommendation to do with those patients who
are at risk for developing liver failure after step 1 before step 2 and
which treatment will be offered to patients that cannot proceed to step
2 based on the scoring system? You mentioned a delay of step 2, but
what will be the next step if you have to delay step 2 further on?
Response From E. Schadde (Zurich, Switzerland):
Thank you for those questions, Professor Bruns. I’ll take that
last question first. So, what do you do for those patients? Our
suggestion is to wait until their liver function is normalized. We
have several patients in the registry who underwent ALPPS and lived
with a split liver without getting completely resected. When ALPPS
was developed, we focused on the high feasibility, but perhaps we
should get away from the idea that we need to get to the second stage
in every patient. We may accept a certain failure, and 97% reaching
the second stage is probably too much. This might cost patient lives.
As far as your second question about chemotherapy is concerned, we
put it into the model and it was not a significant risk factor. Regarding
the question about the usefulness of the score, we used the ISGLS and
the MELD score after stage 1 because we found that stage 1 ALPPS
was a liver function test in its own right. Certainly, it would be a good
idea to develop a comprehensive risk score with data exclusively
before stage 1, and Drs. Clavien and Petrowsky in Zurich are
underway to develop such a score.
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